India's pharma sector is racing toward $130 billion. And 70% of companies can't fill the roles they need to get there.
Healthcare and pharma jobs grew 62% year-on-year in early 2025 โ the fastest surge in any sector. Pay increments are averaging 9.6%, outpacing India Inc's 8.8%. On paper, this looks like a talent magnet. On the ground, it's a talent crisis dressed up as a growth story.
The sector is changing faster than its workforce can adapt. India's pharma industry was built on manufacturing scale and generic drug dominance. The next phase โ biosimilars, AI-led drug discovery, personalised medicine, digital health โ demands a categorically different talent profile.
The hardest roles to fill are the ones that didn't exist five years ago. Pharmacovigilance specialists with AI-assisted signal detection. Regulatory affairs managers fluent in FDA, EMA, and PMDA simultaneously. Bioprocess engineers bridging wet lab and digital analytics. These aren't niche anymore โ they're mission-critical. And the pipelines for them are thin.
Hardest-to-fill roles right now:
Pharmacovigilance โ Critical shortage; AI-hybrid profiles barely exist
Regulatory Affairs โ Multi-market gap; most professionals know only one regulatory body
AI / Drug Discovery โ 20% salary premium; supply nowhere near demand
QA / QC (GMP-certified) โ High churn as GCC competition pulls experienced talent away
Pharma GCCs are compressing the already-thin talent pool further โ white-collar roles like clinical data management, medical writing, and regulatory operations are increasingly housed in GCCs offering higher pay and better career trajectories. Attrition is a structural problem, not a cyclical one.
Eastern India remains an underutilised talent base. Kolkata has a documented pharma ecosystem โ Bengal Chemicals, WBCIL (India's No. 1 API supplier), and a biotech cluster anchored by IIT Kharagpur and IISER Kolkata. Bhubaneswar hosts government-supported pharma parks. API development, bulk drug synthesis, QA/QC, and generics formulation talent exists here โ at lower cost and with better retention than western hubs.
The pharma talent problem in 2026 is not about volume โ it's about sophistication. Hybrid professionals combining scientific depth with digital fluency and regulatory breadth take years to develop. Organisations building pipelines into Eastern India's life sciences talent base today are making a three-year bet the data strongly supports.
Professionals may share profiles at:
jobs.careersatcore.com/
Hiring enquiries: rajiv@careersatcore.com
#PharmaHiring #HealthcareJobs2026 #TalentIntelligence #Pharmacovigilance #EasternIndia #LifeSciences